CTI BioPharma announces pacritinib program update following type B meeting with FDA
CTI BioPharma announced that it recently conducted a Type B meeting with the FDA for its lead product candidate pacritinib. The dosing for the Phase 3 study will be determined using the results of the PAC203 Phase 2 study. PAC203 is expected to complete enrollment by the end of 2018. July 18, 2018